ALX Oncology Holdings Inc cash flow statement

In fiscal 2022, ALX Oncology Holdings Inc's operations generated −$89.2m of cash; it spent $1.4m on capital projects, leaving free cash flow of −$90.7m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

ALX Oncology Holdings Inc: cash flow statement, annual
Fiscal year	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022
Cash from operations	−13	−14	−38	−68	−89
Depreciation and amortisation	0	0	0	0	0
Stock-based pay	0	0	5	14	24
Capital spending	1	0	0	1	1
Free cash flow	−14	−15	−38	−69	−91
Free cash flow after stock pay	−14	−15	−44	−83	−114
Share buybacks	0	—	—	—	—
Shares issued	—	—	368	—	—

US$ millions unless shown otherwise. Fiscal quarters.

ALX Oncology Holdings Inc: cash flow statement, quarterly
Quarter	2019 Q2Jun 2019	2019 Q3Sept 2019	2019 Q4Dec 2019	2020 Q1Mar 2020	2020 Q2Jun 2020	2020 Q3Sept 2020	2020 Q4Dec 2020
Cash from operations	—	−3	−3	−9	−6	−10	−14
Depreciation and amortisation	0	0	0	0	0	0	0
Stock-based pay	0	0	0	0	3	1	2
Capital spending	—	0	−0	0	0	0	0
Free cash flow	—	−3	−3	−9	−6	−10	−14
Free cash flow after stock pay	—	−3	−3	−9	−9	−10	−15
Shares issued	—	—	—	—	—	—	196

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from ALX Oncology Holdings Inc's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to ALX Oncology Holdings Inc.